FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas

Blood

Volumn 127, Issue 6, 2016, Pages 739-748

  Szydlowski, Maciej ^a   Kiliszek, Przemyslaw ^a   Sewastianik, Tomasz ^a   Jablonska, Ewa ^a   Bialopiotrowicz, Emilia ^a   Gorniak, Patryk ^a   Polak, Anna ^a   Markowicz, Sergiusz ^b   Nowak, Eliza ^b   Grygorowicz, Monika A ^b   Prochorec Sobieszek, Monika ^a   Szumera Cieckiewicz, Anna ^a   Malenda, Agata ^a   Lech Maranda, Ewa ^a,c   Warzocha, Krzysztof ^a   Juszczynski, Przemyslaw ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BREAKPOINT CLUSTER REGION PROTEIN; FOSTAMATINIB; PROTEIN KINASE B; PROTEIN KINASE SYK; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHR; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LIPOGENESIS; LYMPHOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; CELL CYCLE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROARRAY ANALYSIS; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; CELL CYCLE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROARRAY ANALYSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 84959341245     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-654111     Document Type: Article

References (38)

1. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5): 1851-1861.
2. Chen L, Monti S, Juszczynski P, et al. SYKdependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230-2237.
3. Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKTdependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23(6):826-838.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
5. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-1874.
6. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014; 11(1):12-23.
7. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
8. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013; 12(3):229-243.
9. Kurosaki T, Takata M, Yamanashi Y, et al. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med. 1994;179(5): 1725-1729.
10. Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J Exp Med. 1995;182(6):1815-1823.
11. Rowley RB, Burkhardt AL, Chao HG, Matsueda GR, Bolen JB. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem. 1995;270(19):11590-11594.
12. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
13. Kloo B, Nagel D, Pfeifer M, et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2011;108(1):272-277.
14. Havranek O, Koehrer S, Comer JM, et al. The B-cell receptor is required for optimal viability, growth, and chemotherapy resistance of diffuse large B-cell lymphoma cell lines of the germinal center B-cell subtype. Blood. 2014;124(21): 493-493.
15. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptortype O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006; 108(10):3428-3433.
16. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24(50):7410-7425.
17. Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27(16):2276-2288.
18. Szydłowski M, Jabłónska E, Juszczýnski P. FOXO1 transcription factor: A critical effector of the PI3K-AKT axis in B-cell development. Int Rev Immunol. 2014;33(2):146-157.
19. Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573-586.
20. Abramson JS, Chen W, Juszczynski P, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol. 2009;144(3): 358-366.
21. Tang ED, Nuñez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem. 1999;274(24): 16741-16746.
22. Polo JM, Juszczynski P, Monti S, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA. 2007; 104(9):3207-3212.
23. Vogel MJ, Xie L, Guan H, et al. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood. 2014;124(20):3118-3129.
24. Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 2007;110(6):2067-2074.
25. Trinh DL, Scott DW, Morin RD, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666-3674.
26. Xie L, Ushmorov A, Leithauser F, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119(15):3503-3511.
27. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14(2): 83-97.
28. Deng X, Zhang W, O-Sullivan I, et al. FoxO1 inhibits sterol regulatory element-binding protein- 1c (SREBP-1c) gene expression via transcription factors Sp1 and SREBP-1c. J Biol Chem. 2012; 287(24):20132-20143.
29. Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem. 2006;281(15): 10105-10117.
30. Krycer JR, Sharpe LJ, Luu W, Brown AJ. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab. 2010; 21(5):268-276.
31. Sanz C, Mellstrom B, Link WA, Naranjo JR, Fernandez-Luna JL. Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic Hrk gene in hematopoietic progenitor cells. EMBO J. 2001; 20(9):2286-2292.
32. Sanz C, Horita M, Fernandez-Luna JL. Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells. Haematologica. 2002; 87(9):903-907.
33. Mathews Griner LA, Guha R, Shinn P, et al. Highthroughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111(6):2349-2354.
34. Paik JH, Kollipara R, Chu G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128(2):309-323.
35. Xie L, Ritz O, Leithauser F, et al. FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma. Oncotarget. 2014;5(14):5392-5402.
36. Go H, Jang JY, Kim PJ, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;6(17): 15035-15049.
37. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13(8):578-591.
38. Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T. Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood. 2008;111(3): 1497-1503.